Table 1. Demographic characteristics and comorbidities of COVID-19 patients at admission to hospital, North-Eastern France, March 2020 (n=1,045 patients).
| Characteristics | All patients n = 1,045 |
Non severe disease n = 621 |
Severe disease n = 424 |
Difference in proportion of the event (CrI) | Pr diff > 0 | |||
|---|---|---|---|---|---|---|---|---|
| Numbera | %a | Numbera | %a | Numbera | %a | |||
| Age, years, mean (SD) | 66.3 (16.0) | 65.6 (17.4) | 67.3 (13.4) | –1.6 (–3.5 to 0.2) | 0.045 | |||
| Male sex | 612 | 58.6 | 309 | 49.8 | 303 | 71.5 | –18.0 (–23.3 to –12.6) | < 0.001 |
| BMIb | ||||||||
| < 25 kg/m2 | 236 | 26.3 | 169 | 32.4 | 67 | 17.9 | Reference | |
| 25–29.9 kg/m2 | 310 | 34.6 | 166 | 31.8 | 144 | 38.4 | –13.0 (–19.9 to –6.1) | < 0.001 |
| ≥ 30 kg/m2 | 351 | 39.1 | 187 | 35.8 | 164 | 43.7 | –13.4 (–20.1 to –6.6) | < 0.001 |
| Comorbidity | ||||||||
| Hypertension | 548 | 52.4 | 317 | 51.0 | 231 | 54.5 | –2.8 (–8.3 to 2.7) | 0.157 |
| Diabetes | 264 | 25.3 | 148 | 23.8 | 116 | 27.4 | –3.4 (–9.4 to 2.7) | 0.139 |
| Active smoking | 36 | 3.4 | 25 | 4.0 | 11 | 2.6 | 3.4 (–5.3 to 11.8) | 0.781 |
| Chronic heart failure | 121 | 11.6 | 75 | 12.1 | 46 | 10.8 | 1.9 (–5.3 to 8.9) | 0.701 |
| Chronic respiratory diseasec | 172 | 16.5 | 93 | 15.0 | 79 | 18.6 | –4.2 (–10.9 to 2.4) | 0.109 |
| Chronic kidney disease | 117 | 11.2 | 68 | 11.0 | 49 | 11.6 | –0.7 (–7.9 to 6.5) | 0.430 |
| Chronic hepatic failure | 11 | 1.1 | 8 | 1.3 | 3 | 0.7 | 1.9 (–7.6 to 11.2) | 0.657 |
| Immunosuppressiond | 48 | 4.6 | 25 | 4.0 | 23 | 5.4 | –2.4 (–10.9 to 6.0) | 0.294 |
| Cancere | 109 | 10.4 | 65 | 10.5 | 44 | 10.4 | 0.4 (–6.9 to 7.6) | 0.540 |
| Haematological malignancye | 32 | 3.1 | 12 | 1.9 | 20 | 4.7 | –5.5 (–14.6 to 3.3) | 0.113 |
| Pregnancy | 15 | 1.4 | 13 | 2.1 | 2 | 0.5 | 4.4 (–4.9 to 13.4) | 0.825 |
| Treatment in the previous month | ||||||||
| NSAIDsf | 51 | 5.0 | 32 | 5.6 | 19 | 4.6 | 1.1 (–7.2 to 9.3) | 0.610 |
| ACE inhibitors | 185 | 17.7 | 107 | 17.2 | 78 | 18.4 | –1.2 (–7.7 to 5.3) | 0.361 |
| AIIRAs | 188 | 18.0 | 110 | 17.7 | 78 | 18.4 | –0.6 (–7.1 to 5.7) | 0.424 |
| Mean time from onset of symptoms to admission (SD), in days | 7.2 (5.3) | 6.9 (5.4) | 7.6 (5.1) | –0.7 (–1.4 to 0.0) | 0.033 | |||
ACE: angiotensin-converting enzyme; AIIRAs: angiotensin II receptor antagonists; BMI: body mass index; CrI: credible interval; diff.: difference; NSAIDs: non-steroidal anti-inflammatory drugs; Pr: probability; SD: standard deviation.
a Numbers and percentages are presented in the column unless specified otherwise by the row heading.
b Data available for 897 patients.
c 60 patients presented with asthma, 54 with chronic obstructive pulmonary disease, 47 with obstructive sleep apnoea and 20 with other chronic respiratory disease (some patients presented with > 1 disease).
d 22 patients presented with solid organ transplantation, 16 with immunosuppressive drugs, two with human immunodeficiency virus and eight with other immunodeficiency.
e Active or in remission.
f Data available for 1,023 patients.
Probabilities near 1 or 0 are both suggestive of an effect, respectively of a positive or negative difference, and are marked in bold.